US › Healthcare

Eikon Therapeutics, Inc. Common Stock (EIKN)

US · Healthcare · Biotechnology

$9.56+4.48%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-83.0M
EPS
$-2.46
EPS estimate
$-1.22

EPS came in at -2.46 against a street estimate of -1.22 — a miss of 101.6%.

Key statistics

Market cap
$498.6M
Forward P/E
0.0
P/B
0.91
Book value
$10.17
EPS (TTM)
$-6.33
52-week high
$17.40
52-week low
$7.90
50-day MA
$10.11
200-day MA
$11.21

Analyst view

with an average price target of $24.80.

Shareholding

Insiders
17.39%
Institutions
66.77%

Largest institutional holders

FundStake
FMR Inc7.09%
BlackRock Inc6.13%
Foresite Capital Management IV, LLC3.59%
Merck & Co Inc3.08%
Foresite Capital Management V, LLC2.44%
T. Rowe Price Investment Management,Inc.2.26%
Capital World Investors2.11%
AllianceBernstein L.P.1.89%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Eikon Therapeutics, Inc. Common Stock — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.